Clinical Trials Logo

Androgenetic Alopecia clinical trials

View clinical trials related to Androgenetic Alopecia.

Filter by:

NCT ID: NCT05348343 Recruiting - Clinical trials for Androgenetic Alopecia

Activated PRP for Treatment of Androgenetic Alopecia

Start date: May 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A clinical trial to assess the effects and safety of PRP activated with pulsed electrical fields (PEFA-PRP) compared with unactivated PRP when used to treat AGA. The design of this small-scale, phase 1b/2a clinical trial is to demonstrate that pulsed electric field activation of autologous PRP results in a controlled release of platelet growth factors and other biologically active molecules that will have a benefit effect on the non-cycling hair follicles in the treated scalp compared to non-activated PRP. This single-center, auto-controlled study will compare the clinical benefit of PEFA-PRP versus non-activated PRP treatment of male patients with AGA.

NCT ID: NCT05324293 Completed - Clinical trials for Androgenetic Alopecia

To Evaluate the Safety, Tolerability and Efficacy in Male and Female With AGA Treated With HMI-115 Over a 24-week Treatment Period

Start date: May 11, 2022
Phase: Phase 1
Study type: Interventional

An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.

NCT ID: NCT05129800 Not yet recruiting - Clinical trials for Androgenetic Alopecia

Efficacy of Platelet-Rich Plasma Versus Mesotherapy in Androgenetic Alopecia: A Retrospective Study

Start date: December 2021
Phase:
Study type: Observational

This is a comparative retrospective study of the efficacy of platelet-rich plasma injections and injections with commercial products advertised to promote hair regrowth for patients with androgenetic alopecia.

NCT ID: NCT05129254 Withdrawn - Clinical trials for Androgenetic Alopecia

Thulium Laser and Topical Platelet Rich Plasma (PRP) vs. PRP Injection for the Treatment of Male Androgenetic Alopecia

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The objective of this clinical study is to compare the safety and efficacy of a laser and topically applied platelet-rich plasma vs. platelet rich plasma injection in the treatment of male-pattern hair loss. Participating subjects will receive up to four (4) monthly treatments and will have a 12 month follow-up period.

NCT ID: NCT04984707 Completed - Clinical trials for Androgenetic Alopecia

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

Start date: January 28, 2019
Phase: Phase 1
Study type: Interventional

The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following Topical Single Ascending Dose Administration

NCT ID: NCT04945226 Completed - Clinical trials for Androgenetic Alopecia

A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001

Start date: September 21, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001

NCT ID: NCT04898166 Completed - Covid19 Clinical Trials

Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).

Start date: December 1, 2020
Phase:
Study type: Observational [Patient Registry]

Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia. Recent studies show severe outcomes of COVID-19 patients specially in males who suffer from androgenetic alopecia, would be significant and is of particular interest of this study and could help further support the hypothesis that anti-androgen therapy might represents an additional potential intervention against severe COVID-19.

NCT ID: NCT04882969 Withdrawn - Clinical trials for Androgenetic Alopecia

Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The objective of this clinical study is to assess the safety and efficacy of using a laser and hair growth factors in the treatment of male-pattern hair loss. Participating subjects will receive up to two (2) treatments per month for 6 months with the laser and post-treatment topically applied hair growth factors and will have a 6 month follow-up period.

NCT ID: NCT04842383 Recruiting - Clinical trials for Androgenetic Alopecia

Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case Series

Hair Regrowth
Start date: April 5, 2021
Phase: Early Phase 1
Study type: Interventional

This is a case series of adult, male and female subjects with androgenetic alopecia (male pattern baldness). A topical hemp oil that is rich in varins (THCV and CBDV) and cannabidiol (CBD) is being used daily for six months to stimulate hair regrowth using Endocannabinoid System (ECS) receptors that are found on hair follicles.

NCT ID: NCT04825561 Completed - Clinical trials for Androgenetic Alopecia

A Study to Evaluate the Efficacy and Safety of AD-208

Start date: June 9, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of AD-208.